Evidence map›Paper›PMID 11796629›Full record

ArticleInfection and immunity2002

Structural decomposition and heterogeneity of commercial lipoteichoic Acid preparations.

Siegfried Morath, Armin Geyer, Ingo Spreitzer, Corinna Hermann, Thomas Hartung

Abstract read
In one paragraph

Article in Infection and immunity, 2002. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 47 papers.

0numbers the graph read from it
0cells of the map it votes in
47citing papers in PubMed
4.0field-weighted citation impact, top 5% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

47 citing papers in PubMed, 175 citations in OpenAlex.

  1. Trial
  2. Article
  3. Article
  4. Article
  5. Type I Lipoteichoic Acid (LTA) Detection by Western Blot.Methods in molecular biology (Clifton, N.J.) · 2024
    Article
  6. Muramyl dipeptide potentiatesFrontiers in immunology · 2024
    Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Generation of glucosylatedRSC chemical biology · 2021
    Article
  12. GtcA is required for LTA glycosylation inCell surface (Amsterdam, Netherlands) · 2020
    Article
  13. Article
  14. Article
  15. Article
  16. Article
  17. Article
  18. Article
  19. Review
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 1 institution in 1 country.

Siegfried MorathUniversity of Konstanz, Biochemical Pharmacology, Konstanz, Germany.
Armin Geyer
Ingo Spreitzer
Corinna Hermann
Thomas Hartung
University of Konstanz · DE

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Fractionation of commercial preparations of lipoteichoic acids (LTA) by hydrophobic interaction chromatography (HIC) and nuclear magnetic resonance spectroscopy revealed very inhomogeneous compositions and decomposition of the LTA structure: LTA content of the preparations averaged 61% for Streptococcus pyogenes, 16% for Bacillus subtilis, and 75% for Staphylococcus aureus. The decomposition was characterized by a loss of glycerophosphate units as well as alanine and N-acetylglucosamine substituents. All preparations contained-to varying degrees-non-LTA, non-lipopolysaccharide (LPS) immunostimulatory components as indicated by their elution profile in HIC, lack of phosphate, and negative Limulus amoebocyte lysate (LAL) test results. After purification, the commercial LTA from Bacillus subtilis and S. pyogenes but not LTA from S. aureus induced the release of tumor necrosis factor alpha, interleukin 1 beta (IL-1beta), IL-6, and IL-10 in human blood. While pure LTA are negative in the LAL assay, endotoxin equivalents of more than 10 ng of LPS/mg of LTA were found in the commercial preparations. Taken together, these data indicate that these crude preparations with relatively high endotoxin contamination are not suitable for characterizing the activation of immune cells by LTA.

Indexed as

Bacillus subtilisHumansInterleukin-1Interleukin-10Interleukin-6LipopolysaccharidesMolecular StructureStaphylococcus aureusStreptococcus pyogenesTeichoic AcidsTumor Necrosis Factor-alphaInterleukin-1Interleukin-10Interleukin-6Lipopolysaccharideslipoteichoic acidTeichoic AcidsTumor Necrosis Factor-alpha

Identifiers

PMID11796629
PMCPMC127707
OpenAlexW2095718564

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.